HypertensionPhase 1NCT07838220
A Study of IBI3016 in Japanese Participants
A Phase 1 study testing IBI3016 Dose 4, IBI3016 Dose 3 and IBI3016 Dose 2 in people with Hypertension, run by Innovent Biologics (Suzhou) Co. Ltd. at 1 site in Japan.
Trial summary
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hypertension
- What is being tested?
- IBI3016 Dose 4, IBI3016 Dose 3 and IBI3016 Dose 2
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteJapan
- Study dates
- 1 Aug 2026to 5 Nov 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Male or female participants aged 18-75 years (inclusive) at the time of informed consent;
- 2. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin;
- 3. Office mean sitting SBP≥ 140 mmHg and < 170 mmHg at screening
Who cannot join
- 1. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea;
- 2. History of orthostatic hypotension
- 3. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor
- 4. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening;
- 5. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Congying Xia contact
Japan1 site, 1 recruiting
- Recruiting
Medical Corporation Heishinkai OPHAC Hospital
Osaka, 532-003
Kotaro Tsushima, +81-6-6395-9000, ophach_chiken@heishinkai.com
About this study
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
- Conditions
- Hypertension
- Being tested
- IBI3016 Dose 4, IBI3016 Dose 3, IBI3016 Dose 2, IBI3016 Dose 1, Placebo
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IBI3016 Dose 4Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 3Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 2Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 1Drug
single doses of IBI3016 administered by subcutaneous injection
PlaceboDrug
single doses of IBI3016 administered by subcutaneous injection
| Study group | Role | What they receive |
|---|---|---|
| IBI3016 Dose1 | Experimental | single doses of IBI3016 administered by subcutaneous injection Receives: Drug: IBI3016 Dose 1 |
| IBI3016 Dose 2 | Experimental | single doses of IBI3016 administered by subcutaneous injection Receives: Drug: IBI3016 Dose 2 |
| IBI3016 Dose4 | Experimental | single doses of IBI3016 administered by subcutaneous injection Receives: Drug: IBI3016 Dose 4 |
| Placebo | Placebo comparator | single doses of Placebo administered by subcutaneous injection Receives: Drug: Placebo |
| IBI3016 Dose3 | Experimental | single doses of IBI3016 administered by subcutaneous injection Receives: Drug: IBI3016 Dose 3 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Adverse Events
Measured: Through 24 weeks, up to approximately 12 months
Secondary outcomes (5)
Plasma Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI3016
Measured: Predose, early post-dose and up to 48 hours postdose
Plasma PK: Area Under the Concentration Versus Time Curve (AUC) of IBI3016
Measured: Predose, Day 1, and up to 48 hours postdose
Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) assessed by OBP and ABPM
Measured: Baseline, Month 3 and Month 6
Change from baseline in serum angiotensinogen (AGT) concentration
Measured: Through 24 weeks, up to approximately 12 months
Urine PK parameter: drug accumulation
Measured: Predose, Day 1, and up to 48 hours postdose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start1 Aug 2026
- Primary completion30 Jan 2027 (estimated)
- Study completion5 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Innovent Biologics (Suzhou) Co. Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07838220
- Sponsor's protocol ID
- CIBI3016A103
- Status last verified
- Sep 2026
- First submitted
- 13 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension
- ClinicalTrials.gov ID
- NCT07838220
- Acronym / sponsor ID
- CIBI3016A103
- Conditions
- Hypertension
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry (pharma, biotech, devices)
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 30 Jan 2027 (estimated)
- Study completion
- 5 Nov 2027 (estimated)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| IBI3016 Dose1 | Experimental | Drug: IBI3016 Dose 1single doses of IBI3016 administered by subcutaneous injection |
| IBI3016 Dose 2 | Experimental | Drug: IBI3016 Dose 2single doses of IBI3016 administered by subcutaneous injection |
| IBI3016 Dose4 | Experimental | Drug: IBI3016 Dose 4single doses of IBI3016 administered by subcutaneous injection |
| Placebo | Placebo comparator | Drug: Placebosingle doses of Placebo administered by subcutaneous injection |
| IBI3016 Dose3 | Experimental | Drug: IBI3016 Dose 3single doses of IBI3016 administered by subcutaneous injection |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- 1. Male or female participants aged 18-75 years (inclusive) at the time of informed consent;
- 2. Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin;
- 3. Office mean sitting SBP≥ 140 mmHg and < 170 mmHg at screening
Key exclusion criteria (5 listed)
- 1. Participants with secondary hypertension, including but not limited to the following conditions: obstructive sleep apnea;
- 2. History of orthostatic hypotension
- 3. Current or history of intolerance to AECI, ARB, ARNI or direct renin inhibitor
- 4. With diseases that require treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors other than hypertension at screening;
- 5. Presence of serious active and uncontrolled physical conditions or medical history, which may be in a dangerous state during the use of the study drug, or interfere with the interpretation of efficacy and safety data of this study, as judged by the investigator prior to randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IBI3016 Dose 4single doses of IBI3016 administered by subcutaneous injection | Drug | IBI3016 Dose4 |
| IBI3016 Dose 3single doses of IBI3016 administered by subcutaneous injection | Drug | IBI3016 Dose3 |
| IBI3016 Dose 2single doses of IBI3016 administered by subcutaneous injection | Drug | IBI3016 Dose 2 |
| IBI3016 Dose 1single doses of IBI3016 administered by subcutaneous injection | Drug | IBI3016 Dose1 |
| Placebosingle doses of IBI3016 administered by subcutaneous injection | Drug | Placebo |
Primary outcome
Number of Participants with Adverse Events
Time frame: Through 24 weeks, up to approximately 12 months
5 secondary outcomes
Plasma Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI3016
Time frame: Predose, early post-dose and up to 48 hours postdose
Plasma PK: Area Under the Concentration Versus Time Curve (AUC) of IBI3016
Time frame: Predose, Day 1, and up to 48 hours postdose
Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) assessed by OBP and ABPM
Time frame: Baseline, Month 3 and Month 6
Change from baseline in serum angiotensinogen (AGT) concentration
Time frame: Through 24 weeks, up to approximately 12 months
Urine PK parameter: drug accumulation
Time frame: Predose, Day 1, and up to 48 hours postdose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Congying Xia contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing IBI3016 Dose 4, IBI3016 Dose 3 and IBI3016 Dose 2 in people with Hypertension, run by Innovent Biologics (Suzhou) Co. Ltd. at 1 site in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wendy Duan (+86 010-87412310, wenjing.duan@innoventbio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Adverse Events (time frame: Through 24 weeks, up to approximately 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.